1-3 of 3
Cory Marvis, MS
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Obatoclax and Bortezomib Therapy Results in Disruption of the p53-Mediated Apoptosis/Autophagy Pathway and Is Associated with Potent Synergistic Anti-Tumor Activity against Rituximab-Chemotherapy-Sensitive and -Resistant B-Cell Lymphoma.

Francisco Hernandez-Ilizaliturri, MD, Ping-Chiao Tsio, MS, Ryan Campagna, BS, Cory Marvis, MS, Wasif Riaz, MD, Elizabeth Gruber, MS, John Gibbs, MD, Myron S. Czuczman, MD
Journal: Blood
Blood (2009) 114 (22): 288.
https://doi.org/10.1182/blood.V114.22.288.288
Published: 2009
Journal Articles

The DAC Inhibitor, LBH589, Is Highly Effective in Both Rituximab-Sensitive and Rituximab-Resistant Lymphomas and Enhances the Anti-Tumor Activity of Bortezomib, Other Chemotherapy Agents, and Anti-CD20 Monoclonal Antibodies.

Francisco J Hernandez-Ilizaliturri, MD, Cory Marvis, MS, Ilir Maraj, MD, Mohammad M Chisti, MD, John Gibbs, MD, Myron S Czuczman
Journal: Blood
Blood (2009) 114 (22): 2715.
https://doi.org/10.1182/blood.V114.22.2715.2715
Published: 2009
Journal Articles

Entinostat (SNDX-275), a Novel DAC Inhibitor, Is Highly Effective in Rituximab- [Chemotherapy]-Sensitive or Rituximab-[Chemotherapy]-Resistant Lymphomas and Has Synergistic Anti-Tumor Activity When Combined with Bortezomib.

Umeer Ashraf, MD, Myron S. Czuczman, MD, Cory Marvis, MS, John Gibbs, MD, Francisco J Hernandez-Ilizaliturri, MD
Journal: Blood
Blood (2009) 114 (22): 3727.
https://doi.org/10.1182/blood.V114.22.3727.3727
Published: 2009